Back to top

Image: Shutterstock

Scoop Up These 3 GARP Stocks to Receive Handsome Returns

Read MoreHide Full Article

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

The strategy helps investors gain exposure to undervalued stocks with impressive prospects. Unlike a blend strategy, a portfolio that uses GARP investing is expected to include stocks that offer the best value and growth investing. Sprouts Farmers Market (SFM - Free Report) , Cencora, Inc. (COR - Free Report) and American Express (AXP - Free Report) are some GARP stocks that hold promise.

GARP Metrics: Mix of Growth & Value Metrics

The GARP strategy seeks to offer an ideal investment by utilizing the best features of value and growth investing. Investors adopting the GARP approach prefer buying stocks priced below the market or any reasonable target determined by fundamental analysis. These stocks also have solid prospects in terms of cash flow, revenues, earnings per share (EPS) and so on.

Growth Metrics

A strong earnings growth history and impressive earnings prospects are the main concepts that GARP investors borrow from the growth investing strategy. However, instead of super-normal growth rates, pursuing stocks with a more stable and reasonable growth rate is a tactic of GARP investors. Hence, growth rates between 10% and 20% are considered ideal under the GARP strategy.

Another metric that growth and GARP investors consider is the return on equity (ROE). GARP investors look for a strong and higher ROE than the industry average to identify superior stocks. Stocks with positive cash flows find precedence under the GARP plan.

Value Metrics

GARP investing prioritizes the popular value metrics — the price-to-earnings (P/E) and price-to-book (P/B) ratios. Though this investing style picks stocks with higher P/E ratios than value investors, it avoids companies with extremely high P/E ratios.

Using the GARP principle, we ran a screen to identify stocks that should offer solid returns in the near term.

Screening Parameters

Along with the criteria discussed in the above section, we have considered a Zacks Rank #1 (Strong Buy) or 2 (Buy).

Last 5-year EPS & projected 3-5-year EPS growth rates between 10% and 20% (Strong EPS growth history and prospects ensure improving business.)

ROE (over the past 12 months) greater than the industry average (Higher ROE than the industry average indicates superior stocks.)

P/E and P/B ratios less than the M-industry average (P/E and P/B ratios less than that of the industry indicate that the stocks are undervalued.)

Here are the three stocks that made it through the screening process:

Sprouts Farmers Market, which operates in a highly fragmented grocery store industry, has a unique model that features fresh produce, a foods section and a vitamin department focused on overall wellness. Moreover, the company has been diversifying its offerings to meet the changing preferences of consumers, who are looking for more health and wellness products. 

The company’s focus on product innovation, emphasis on e-commerce, expansion of private label offerings and targeted marketing with everyday great pricing bodes well. It has been lowering operational complexity, optimizing production, improving in-stock position and updating to smaller format stores. These efforts helped post better-than-expected fourth-quarter 2024 results, wherein both the top and the bottom lines grew year over year. Buoyed by the performance, Sprouts Farmers provided a decent 2025 view. The company expects net sales to rise between 10.5% and 12.5%, with comps anticipated to increase in the range of 4.5-6.5%. SFM’s strong sales growth, margin expansion and disciplined financial management position it as a compelling investment opportunity.

This Zacks Rank #1 stock has surged 128.8% in the past year. It has a trailing four-quarter earnings surprise of 15.12%, on average. The Zacks Consensus Estimate for SFM’s 2025 earnings has moved north by 8.3% to $4.56 per share over the past 30 days. You can see the complete list of today's Zacks #1 Rank stocks here

Cencora is one of the world’s largest pharmaceutical service companies. It focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company is well-positioned to deliver long-term sustainable growth due to its diverse and inclusive teams.

This Zacks Rank #2 company is an ideal partner for manufacturers looking to launch products. This is due to its extensive worldwide distribution network and global platform of commercialization services. Thanks to its growing presence in the pharmaceutical industry, Cencora can establish partnerships with pharmaceutical companies at an early stage of product development and market itself as an integrated partner capable of assisting in the successful commercialization of its products (in addition to providing logistics and distribution services). These factors are likely to have favored the stock’s growth.

Cencora has risen 5.7% in the past year. It has a trailing four-quarter earnings surprise of 4.94%, on average. The Zacks Consensus Estimate for COR’s fiscal 2025 earnings has moved north by 1.3% to $15.29 per share over the past 30 days.

American Express Company is a diversified financial services company offering charge and credit payment card products and travel-related services worldwide. Its growth initiatives, like launching new products, reaching new agreements and forging alliances, are boosting its revenues. 

Consumer spending on travel and entertainment, which carries higher margins for AmEx, is advancing well. Its focus on millennials and Gen-Z consumers who exhibit strong dining preferences positions the company for long-term growth. Its solid cash-generation abilities enable the pursuit of business investments, share buybacks and dividend payments.

AmEx has rallied 34.1% in the past year. It has a trailing four-quarter earnings surprise of 6.89%, on average. The Zacks Consensus Estimate for AXP’s 2025 earnings has remained steady at $15.32 per share over the past 30 days.

Get the remaining stocks on the list and start testing this and other ideas. It can all be done with the Research Wizard stock picking and back-testing software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in and see what gems come out.

Click here to sign up for a free trial of the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks' portfolios and strategies are available at:
https://www.zacks.com/performance.


Zacks' 7 Best Strong Buy Stocks (New Research Report)


Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.


Click Here, It's Really Free

Published in